PLS-PM results indicated that Tau positively affected the Nrf2/Keap1 pathway and negatively modulated the TLR4/NF-κB pathway, thereby improving intestinal barrier function and alleviating liver fibrosis. The gene discussed is MAPT; the disease is Hepatic fibrosis.